Literature DB >> 20594132

Crohn's disease as an immunodeficiency.

Bu'Hussain Hayee1, Farooq Z Rahman, Gavin Sewell, Andrew M Smith, Anthony W Segal.   

Abstract

The pathogenesis of Crohn's disease (CD) has widely been regarded as the consequence of a dysregulated T-cell-mediated response to intestinal microbes, and the majority of the worldwide research effort has focused on characterizing and treating the chronic inflammatory phase of the disease. However, recent molecular biological and clinical investigations indicate that CD is actually a primary immunodeficiency. At first counter-intuitive, the apparent paradox of a pathogenic innate immune defect can be linked mechanistically to the granulomatous chronic inflammation characteristic of the disease. Genome-wide association studies have corroborated the involvement of innate immune dysfunction in the pathogenesis of CD, but less than 20% of the heritable risk is accounted for. By contrast, in vitro and in vivo stimulation of the immune system has highlighted novel areas of interest that may lead to the development of targeted therapeutic and diagnostic tools.

Entities:  

Mesh:

Year:  2010        PMID: 20594132      PMCID: PMC4618314          DOI: 10.1586/eci.10.32

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  141 in total

1.  Contributions of IBD5, IL23R, ATG16L1, and NOD2 to Crohn's disease risk in a population-based case-control study: evidence of gene-gene interactions.

Authors:  Toshihiko Okazaki; Ming-Hsi Wang; Patricia Rawsthorne; Michael Sargent; Lisa Wu Datta; Yin Yao Shugart; Charles N Bernstein; Steven R Brant
Journal:  Inflamm Bowel Dis       Date:  2008-11       Impact factor: 5.325

Review 2.  Modification of bile acids by intestinal bacteria.

Authors:  R Lewis; S Gorbach
Journal:  Arch Intern Med       Date:  1972-10

3.  Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection.

Authors:  Maria Van der Sluis; Barbara A E De Koning; Adrianus C J M De Bruijn; Anna Velcich; Jules P P Meijerink; Johannes B Van Goudoever; Hans A Büller; Jan Dekker; Isabelle Van Seuningen; Ingrid B Renes; Alexandra W C Einerhand
Journal:  Gastroenterology       Date:  2006-07       Impact factor: 22.682

4.  Neutrophil dysfunction in Crohn's disease.

Authors:  A W Segal; G Loewi
Journal:  Lancet       Date:  1976-07-31       Impact factor: 79.321

5.  Stimulation of alpha7 nicotinic acetylcholine receptor inhibits CD14 and the toll-like receptor 4 expression in human monocytes.

Authors:  Ryosuke Hamano; Hideo Kohka Takahashi; Hiromi Iwagaki; Tadashi Yoshino; Masahiro Nishibori; Noriaki Tanaka
Journal:  Shock       Date:  2006-10       Impact factor: 3.454

6.  Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease.

Authors:  J O Lindsay; K Whelan; A J Stagg; P Gobin; H O Al-Hassi; N Rayment; M A Kamm; S C Knight; A Forbes
Journal:  Gut       Date:  2005-09-14       Impact factor: 23.059

7.  Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis.

Authors:  M Boirivant; M Marini; G Di Felice; A M Pronio; C Montesani; R Tersigni; W Strober
Journal:  Gastroenterology       Date:  1999-03       Impact factor: 22.682

8.  Role of nod2 in the response of macrophages to toll-like receptor agonists.

Authors:  Anne-Laure Pauleau; Peter J Murray
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

9.  Intracellular survival of wild-type Salmonella typhimurium and macrophage-sensitive mutants in diverse populations of macrophages.

Authors:  N A Buchmeier; F Heffron
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

10.  Infectious gastroenteritis and risk of developing inflammatory bowel disease.

Authors:  Chad K Porter; David R Tribble; Pablo A Aliaga; Heather A Halvorson; Mark S Riddle
Journal:  Gastroenterology       Date:  2008-06-05       Impact factor: 22.682

View more
  11 in total

Review 1.  New frontiers in primary immunodeficiency disorders: immunology and beyond….

Authors:  Eleonora Gambineri
Journal:  Cell Mol Life Sci       Date:  2011-10-19       Impact factor: 9.261

2.  Successful treatment of asymptomatic or clinically terminal bovine Mycobacterium avium subspecies paratuberculosis infection (Johne's disease) with the bacterium Dietzia used as a probiotic alone or in combination with dexamethasone: Adaption to chronic human diarrheal diseases.

Authors:  Robert E Click
Journal:  Virulence       Date:  2011-03-01       Impact factor: 5.882

Review 3.  Intestinal dendritic cell and macrophage subsets: Tipping the balance to Crohn's disease?

Authors:  M K Magnusson; M J Wick
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2011-03

Review 4.  What is wrong with granulocytes in inflammatory bowel diseases?

Authors:  Adam P Levine; Anthony W Segal
Journal:  Dig Dis       Date:  2013-11-14       Impact factor: 2.404

5.  Site-Specific Immunomodulator: A Novel Treatment for Crohn's Disease.

Authors:  Brian Bressler; Kevin P Bethel; Ralf Kleef; Sophie L Reynolds; Simon Sutcliffe; David W Mullins; Hal Gunn
Journal:  Gastroenterol Res Pract       Date:  2015-05-12       Impact factor: 2.260

6.  Dietary Fiber Intake is Associated with Increased Colonic Mucosal GPR43+ Polymorphonuclear Infiltration in Active Crohn's Disease.

Authors:  Mingli Zhao; Weiming Zhu; Jianfeng Gong; Lugen Zuo; Jie Zhao; Jing Sun; Ning Li; Jieshou Li
Journal:  Nutrients       Date:  2015-07-01       Impact factor: 5.717

7.  The Drosophila CD36 Homologue croquemort Is Required to Maintain Immune and Gut Homeostasis during Development and Aging.

Authors:  Aurélien Guillou; Katia Troha; Hui Wang; Nathalie C Franc; Nicolas Buchon
Journal:  PLoS Pathog       Date:  2016-10-25       Impact factor: 6.823

8.  A Potential 'Curative' Modality for Crohn's Disease---Modeled after Prophylaxis of Bovine Johne's Disease.

Authors:  Robert E Click
Journal:  Mycobact Dis       Date:  2012-05-31

9.  Evidence for non-neutralizing autoantibodies against IL-10 signalling components in patients with inflammatory bowel disease.

Authors:  Natalie Frede; Erik-Oliver Glocker; Jennifer Wanders; Karin R Engelhardt; Wolfgang Kreisel; Frank M Ruemmele; Bodo Grimbacher
Journal:  BMC Immunol       Date:  2014-02-28       Impact factor: 3.615

10.  Principal component analysis characterizes shared pathogenetics from genome-wide association studies.

Authors:  Diana Chang; Alon Keinan
Journal:  PLoS Comput Biol       Date:  2014-09-11       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.